[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Honore et al., 2012 - Google Patents

Biomarkers for early diagnosis of AKI in the ICU: ready for prime time use at the bedside?

Honore et al., 2012

View HTML @Full View
Document ID
17564604484443146298
Author
Honore P
Jacobs R
Joannes-Boyau O
Verfaillie L
De Regt J
Van Gorp V
De Waele E
Boer W
Collin V
Spapen H
Publication year
Publication venue
Annals of intensive care

External Links

Snippet

Because of its still rising incidence and high mortality rate in intensive care unit (ICU) patients, early recognition of acute kidney injury (AKI) remains a critical issue. Surprisingly, effective biomarkers for early detection and hence appropriate and timely therapy of AKI …
Continue reading at link.springer.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/573—Immunoassay; Biospecific binding assay for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Similar Documents

Publication Publication Date Title
Honore et al. Biomarkers for early diagnosis of AKI in the ICU: ready for prime time use at the bedside?
Keller et al. Management of metformin-associated lactic acidosis by continuous renal replacement therapy
Goldstein et al. Acute kidney injury in childhood: should we be worried about progression to CKD?
Tuladhar et al. Rapid detection of acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass
Belcher et al. Clinical applications of biomarkers for acute kidney injury
Medić et al. Kidney injury molecule‐1 and cardiovascular diseases: from basic science to clinical practice
Taub et al. Role of biomarkers in the diagnosis and prognosis of acute kidney injury in patients with cardiorenal syndrome
Xu et al. Gender differences in age-related decline in glomerular filtration rates in healthy people and chronic kidney disease patients
Loghman-Adham et al. Detection and management of nephrotoxicity during drug development
Maiwall et al. Acute kidney injury in acute on chronic liver failure
De Vecchis et al. Cardiorenal syndrome type 2: from diagnosis to optimal management
Maxwell et al. Acute kidney injury in the critically ill
Casanova et al. Urinary transferrin pre-emptively identifies the risk of renal damage posed by subclinical tubular alterations
Furuichi et al. Clinicopathological features of fast eGFR decliners among patients with diabetic nephropathy
Tarapan et al. High sensitivity Troponin-I levels in asymptomatic hemodialysis patients
Lin et al. Urinary neutrophil gelatinase-associated lipocalin and clinical outcomes in chronic kidney disease patients
Neyra et al. Dipstick albuminuria and acute kidney injury recovery in critically ill septic patients
Masania et al. Urinary Metabolomic Markers of Protein Glycation, Oxidation, and Nitration in Early‐Stage Decline in Metabolic, Vascular, and Renal Health
Shen et al. Serum cystatin C reflects angiographic coronary collateralization in stable coronary artery disease patients with chronic total occlusion
Bashier et al. Cystatin C and its role in patients with type 1 and type 2 diabetes mellitus
Honore et al. The early biomarker of acute kidney injury: in search of the Holy Grail
Gist et al. Milrinone dosing issues in critically ill children with kidney injury: a review
Alhaddad et al. Neutrophil gelatinase‐associated lipocalin: a new marker of renal function in C‐related end stage liver disease
Itenov et al. ABO blood types and sepsis mortality
Bang et al. Cystatin-C is associated with partial recovery of kidney function and progression to chronic kidney disease in living kidney donors: Observational study